glp-1 drugs pharmaceutical companies news 2025 Pipeline Update: November - Prime Therapeutics In May 2025, major GLP-1

Their approach adopted a single-target inhibition strategy, primarily targeting FA synthesis inhibition through TOFA, while their design focused on alleviating oxidative lipid accumulation, a key factor impeding antigen cross-presentation, and placed greater emphasis on the adaptability of in situ vaccination and durable immune memory formation

There are plans to test butyrate supplements as well, given preclinical evidence that butyrate reduces demyelination and enhances remyelination in the CNS

The amino acids and vitamins present in Lipo-C injections can help boost the bodys metabolism, increase energy levels, and improve overall fat burning

Coffey MD, Cole RA, Colles SM, Chisolm GM

Research on EGCGs long-term safety reveals complex considerations for therapeutic applications